Zydus Cadila’s Covid-19 vaccine: How it compares with peers, manufacturing capacities and challenges, explained

Zydus Cadila says its ZyCoV-D vaccine had very good results in Phase 1 and 2 trials. Dosing of participants in Phase 3 has been completed and the data analysis process is underway. However, not a single vaccine using its unique platform has been approved anywhere in the world. ZyCoV-D is also a three-dose vaccine, which could post logistical and administration challenges and weigh on pricing.

from Moneycontrol Business News https://www.moneycontrol.com/news/business/zydus-cadila’s-covid-19-vaccine-how-it-comparespeers-manufacturing-capacitieschallenges-explained_15028681.html